THE IMPERATIVE TO STUDY MEDICAL TREATMENTS IN WOMEN

Hadine Joffe, MD, MSc
Executive Director, Connors Center for Women’s Health and Gender Biology
Paula A. Johnson Associate Professor of Psychiatry in the Field of Women’s Health
Director, Women’s Hormone & Aging Research Program
Vice Chair for Psychiatry Research
Brigham & Women’s Hospital, Harvard Medical School
UNDER-ENROLLMENT OF WOMEN IN CLINICAL TRIALS

Representation of Women in Recent Phase 3 Trials

- Cancer: Immunotherapy: 33% women
- HIV: 0% women

Female Representation by Clinical Trial Phase
- Phase 1: 33%
- Phase 2: 48%
- Phase 3: 41%

F.D.A. Approves New H.I.V.-Prevention Drug, but Not for Everyone

The New York Times
October 4, 2019
SEX DIFFERENCES IN SIDE EFFECTS OF SLEEP MEDICINES

Sleep medicine levels stay higher in women’s bodies for longer after each dose.
CRITICAL NEED TO PERSONALIZE PREVENTION AND TREATMENT FOR BOTH MEN AND WOMEN
VISION

To transform drugs, devices, and digital solutions for diseases that are exclusive, predominate, or differential in women.
“It is more important to know what sort of person has a disease than to know what sort of disease a person has”

Hippocrates
460 BC – 370 BC
SAVE THE DATE: NOVEMBER 13, 2020 | WESTIN COPLEYS, BOSTON MA

NATIONAL SUMMIT ON THE HEALTH OF WOMEN
INNOVATING TO OPTIMIZE TREATMENTS

PRESENTED BY
BRIGHAM HEALTH
BRIGHAM AND WOMEN’S
Mary Horrigan Connors Center
for Women’s Health and Gender Biology

- CELEBRATE PROGRESS IN WOMEN’S HEALTH RESEARCH
- LEARN AND CONNECT WITH THE BROADER WOMEN’S HEALTH BIOSCIENCE ECOSYSTEM
- ENGAGE WITH SEX- AND GENDER-PRECISION MEDICINE COMMUNITY
- MEET EXPERTS FROM RELEVANT DISCIPLINES IN WOMEN’S HEALTH RESEARCH